Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in Chemoradiotherapy for Gastrointestinal Cancers: From Bench to Bedside
share announcement

Advances in Chemoradiotherapy for Gastrointestinal Cancers: From Bench to Bedside

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (30 March 2024) | Viewed by 678

Special Issue Editors

Dr. Reiko Ashida

E-Mail Website
Guest Editor
Departments of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan
Interests: pancreatic cancer; eus; early diagnosis; chemoradiation therapy; interventional eus; gene therapy; personalized medicine; artificial intelligence
Dr. Ryoji Takada

E-Mail Website
Guest Editor
Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan
Interests: pancreatic cancer; locally advanced; ERCP; EUS; neuroendocrine tumor; oligometastasis

Special Issue Information

Dear Colleagues,

This Special Issue aims to provide a comprehensive overview of the current advancements in chemoradiotherapy strategies for gastrointestinal (GI) cancers. It will cover preclinical and clinical research, focusing on the multidisciplinary approach to improve treatment outcomes and patient care. The Special Issue will explore novel combination therapies, including targeted agents, immunotherapy and radiation sensitizers, to enhance the efficacy of chemoradiotherapy. It will address the challenges associated with GI cancers, such as esophageal, gastric, pancreatic, liver, colorectal and biliary cancers, and discuss personalized treatment approaches. Additionally, the Special Issue will emphasize the development and application of innovative imaging techniques, radiation delivery methods and biomarkers for treatment response prediction and therapy monitoring. It will delve into supportive care strategies and the management of treatment-related toxicities to optimize patient quality of life during chemoradiotherapy. Overall, this Special Issue will serve as a platform for disseminating cutting-edge research and fostering collaborations to advance the field of chemoradiotherapy for GI cancers, ultimately leading to improved patient outcomes and survival rates.

Dr. Reiko Ashida
Dr. Ryoji Takada
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chemoradiotherapy
  • pancreatic cancer
  • biomarkers
  • multidisciplinary approach
  • gastrointestinal cancers

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 1331 KiB  
Article
Evaluation of Helium Ion Radiotherapy in Combination with Gemcitabine in Pancreatic Cancer In Vitro
by Bahar Cepni, Thomas Tessonnier, Ivana Dokic, Stephan Brons, Bouchra Tawk, Andrea Mairani, Amir Abdollahi, Jürgen Debus, Klaus Herfarth and Jakob Liermann
Cancers 2024, 16(8), 1497; https://doi.org/10.3390/cancers16081497 - 14 Apr 2024
Viewed by 404
Abstract
Background: Pancreatic cancer is one of the most aggressive and lethal cancers. New treatment strategies are highly warranted. Particle radiotherapy could offer a way to overcome the radioresistant nature of pancreatic cancer because of its biological and physical characteristics. Within particles, helium ions [...] Read more.
Background: Pancreatic cancer is one of the most aggressive and lethal cancers. New treatment strategies are highly warranted. Particle radiotherapy could offer a way to overcome the radioresistant nature of pancreatic cancer because of its biological and physical characteristics. Within particles, helium ions represent an attractive therapy option to achieve the highest possible conformity while at the same time protecting the surrounding normal tissue. The aim of this study was to evaluate the cytotoxic efficacy of helium ion irradiation in pancreatic cancer in vitro. Methods: Human pancreatic cancer cell lines AsPC-1, BxPC-3 and Panc-1 were irradiated with photons and helium ions at various doses and treated with gemcitabine. Photon irradiation was performed with a biological cabin X-ray irradiator, and helium ion irradiation was performed with a spread-out Bragg peak using the raster scanning technique at the Heidelberg Ion Beam Therapy Center (HIT). The cytotoxic effect on pancreatic cancer cells was measured with clonogenic survival. The survival curves were compared to the predicted curves that were calculated via the modified microdosimetric kinetic model (mMKM). Results: The experimental relative biological effectiveness (RBE) of helium ion irradiation ranged from 1.0 to 1.7. The predicted survival curves obtained via mMKM calculations matched the experimental survival curves. Mainly additive cytotoxic effects were observed for the cell lines AsPC-1, BxPC-3 and Panc-1. Conclusion: Our results demonstrate the cytotoxic efficacy of helium ion radiotherapy in pancreatic cancer in vitro as well as the capability of mMKM calculation and its value for biological plan optimization in helium ion therapy for pancreatic cancer. A combined treatment of helium irradiation and chemotherapy with gemcitabine leads to mainly additive cytotoxic effects in pancreatic cancer cell lines. The data generated in this study may serve as the radiobiological basis for future experimental and clinical works using helium ion radiotherapy in pancreatic cancer treatment. Full article
(This article belongs to the Special Issue Advances in Chemoradiotherapy for Gastrointestinal Cancers: From Bench to Bedside)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop